Prognostic and predictive potential of CXCL11 in endocrine resistance in breast cancer

The Predictive Power of the Breast Cancer Index (H/I) Biomarker-SABCS 2022Подробнее

Providing Predictive and Prognostic Biomarkers for Breast Cancer From the TAILORx TrialПодробнее

Overcoming Endocrine Resistance in Breast CancerПодробнее

Endocrine-resistance breast cancersПодробнее

Composite biomarkers predictive of palbociclib + endocrine treatment benefit in early breast cancerПодробнее

Circumventing Endocrine Resistance in Breast CancerПодробнее

Assessing immune biomarkers of response to anthracyclines in breast cancerПодробнее

Endocrine Resistance-Causing Genes in Breast Cancer | OncotargetПодробнее

Endocrine Resistance: Mechanisms and Treatment StrategiesПодробнее

The role of immunotherapy in endocrine-refractory luminal breast cancerПодробнее

Endocrine Resistance in HR+ Metastatic Breast CancerПодробнее

Dr. Goldstein on Endocrine Resistance Therapy in Early- Stage Breast CancerПодробнее

Therapeutic strategies to maximize sensitivity to endocrine therapy in breast cancerПодробнее

Standardizing Extended Endocrine Therapy RecommendationsПодробнее

Endocrine therapy in premenopausal women with HR+ breast cancerПодробнее

Endocrine therapy resistance in ER+ metastatic breast cancerПодробнее

Treating ER+ breast cancer patients with endocrine therapy resistanceПодробнее

Dr. Cristofanilli on Endocrine Therapy for Breast CancerПодробнее